In 660 biopsy-naive men with equivocal or non-suspicious MRI but high clinical risk, PSMA-11 PET-CT-guided biopsy was non-inferior to systematic biopsy for detecting significant prostate cancer (12% vs 16%) and avoided biopsy in 49%.
RCTn = 660
Buteau et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial